Ryan Scott

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com

Articles

Dissemination vs Misinformation: Social Media’s Role in the Evolution of Cancer Care

August 28th 2024

As the dissemination of information in oncology is spread using social media platforms, the potential for misinformation remains a key hurdle.

Bispecific Antibody De-Escalation: Varying Dosing Strategies Aim to Improve Safety, Maintain Efficacy in R/R Myeloma

August 27th 2024

Rahul Banerjee MD, FACP, discusses various dosing strategies and schedules for bispecific antibodies in multiple myeloma.

Biomarker-Driven Approaches Could Refine Treatment Selection in RCC

August 26th 2024

Emre Yekedüz, MD, discusses the exploration of biomarker-driven therapeutic approaches in renal cell carcinoma.

Time-Limited Bispecific Antibodies Could Represent Next Shift in Myeloma Treatment

August 26th 2024

Rahul Banerjee MD, FACP, discusses the rapidly evolving therapeutic landscape of bispecific antibodies in the treatment of patients with multiple myeloma.

CDK4/6 Inhibitors, ADCs, and PI3K Inhibitors Individualize HR+ Breast Cancer Management

August 26th 2024

Shipra Gandhi, MD, discusses the evolution of CDK4/6 inhibitors and ADCs across breast cancer subtypes.

DREAMM-7 and DREAMM-8 Data Support Belantamab Mafodotin–Based Combos in R/R Myeloma

August 24th 2024

Suzanne Trudel, MSc, MD, discusses updated data from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin–based regimens in R/R multiple myeloma.

INV724 Earns FDA Rare Pediatric Disease, Orphan Drug Designations for Neuroblastoma

August 23rd 2024

The FDA has awarded rare pediatric disease designation and orphan drug designation to INV724 for the treatment of neuroblastoma.

Erdafitinib Wins EU Approval for FGFR3+ Unresectable, Metastatic Urothelial Carcinoma

August 23rd 2024

Erdafitinib was approved by the European Commission for pretreated unresectable or metastatic urothelial carcinoma harboring FGFR3 alterations.

Olaparib Monotherapy Elicits Responses in HRR+ Prostate Cancer With High-Risk Biochemical Recurrence

August 22nd 2024

Olaparib produced responses in high-risk, biochemically recurrent prostate cancer with HRR alterations, particularly BRCA2 alterations.

Case Study Highlights an Approach to Adjuvant Treatment in RCC

August 22nd 2024

Emre Yekedüz, MD, discusses a case study shared via an OncLive X poll on the adjuvant treatment of clear cell renal cell carcinoma.

Adjuvant Pembrolizumab Does Not Affect Long-Term HRQOL in Stage III Melanoma

August 21st 2024

Adjuvant pembrolizumab did not have a significant impact on long-term HRQOL outcomes in patients with resected stage III melanoma.

Dr Hernandez-Ilizaliturri on the Use of CAR T-Cell Therapy in R/R Multiple Myeloma

August 19th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Hood on the Association Between BRCA Mutations and Primary Tumor Location in PDAC

August 19th 2024

Ryan Hood, BA, discusses a study investigating the association between BRCA1/2 pathogenic variants and primary tumor location in pancreatic cancer.

Subsequent Therapy Shows No Difference in OS Following IO/TKI-Based Treatment in RCC

August 19th 2024

Neil J. Shah, MBBS, discusses real-world outcomes of patients with metastatic RCC receiving treatment in the post-IO/TKI setting following progression.

Retrospective Study Exemplifies the Environmental and Health Impacts of Decentralizing Cancer Care

August 18th 2024

Andrew Hantel, MD, discusses environmental and health impacts of decentralizing cancer care in response to high emissions generated by US health care.

Potentially Modifiable Eligibility Criteria Drive Enrollment Disparities in AML Clinical Trials

August 16th 2024

Andrew Hantel, MD, discusses the evaluation of eligibility criteria in acute myeloid leukemia clinical trials that may perpetuate racial disparities.

FDA Grants Priority Review to Vimseltinib in Tenosynovial Giant Cell Tumor

August 16th 2024

The FDA has accepted an NDA for vimseltinib for the treatment of patients with tenosynovial giant cell tumor, with a PDUFA date of February 17, 2025.

Time to Next Therapy Demonstrates Potential as an Intermediate End Point in Metastatic RCC

August 16th 2024

Renee Maria Saliby, MD, MS, discusses potential intermediate end points for overall survival in previously treated metastatic renal cell carcinoma.

Linvoseltamab Demonstrates Deep, Durable Responses in R/R Myeloma Ahead of FDA Action Date

August 15th 2024

Suzanne Lentzsch, MD, PhD, discusses updated data from the LINKER-MM1 study of linvoseltamab in relapsed/refractory multiple myeloma.

Targeted Therapy Combinations Could Represent Next Wave of Treatments in Follicular Lymphoma

August 15th 2024

Geoffrey Shouse, DO, PhD, discusses the benefits of utilizing targeted therapy approaches in the treatment of patients with follicular lymphoma.

NEXT PAGE
PREVIOUS PAGE